0.64

2.87% -0.0189

After Hours: .62 -0.02 -3.13%

Zyversa Therapeutics Inc (ZVSA)

Overview News Price History Financials Why ZVSA Down? Discussions Forecast

Zyversa Therapeutics Inc stock is traded at $0.64, with a volume of 1.27M. It is down -2.87% in the last 24 hours and up +4.94% over the past month. ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Previous Close:

$0.6589

Open:

$0.67

24h Volume:

1.27M

Relative Volume:

0.39

Market Cap:

$3.05M

Revenue:

Net Income/Loss:

$-21.33M

P/E Ratio:

-0.00563

EPS:

-113.7479

Net Cash Flow:

$-9.12M

1W Performance:

+18.52%

1M Performance:

+4.94%

6M Performance:

-40.40%

1Y Performance:

-84.31%

1-Day Range:

$0.615

$0.6997

1-Week Range:

$0.518

$0.74

52-Week Range:

$0.4728

$6.30

Zyversa Therapeutics Inc Stock (ZVSA) Company Profile

Name

Zyversa Therapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (671)

Phone

908-370-5102

Address

217 W. MAIN STREET, SOMERVILLE

Employee

Twitter

Next Earnings Date

2024-08-19

Latest SEC Filings

ZVSA's Discussions on Twitter

Compare ZVSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVSA Zyversa Therapeutics Inc	0.64	2.59M	0	-21.33M	-9.12M	-113.75
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Zyversa Therapeutics Inc Stock (ZVSA) Latest News

May 20, 2025

ZVSA: ZyVersa Therapeutics' IC 100 Shows Promise in PD Treatment - GuruFocus

May 20, 2025

ZyVersa’s IC 100 shows promise in Parkinson’s treatment By Investing.com - Investing.com India

May 20, 2025

ZyVersa Therapeutics highlights publication of data on IC 100 - TipRanks

May 20, 2025

ZyVersa’s IC 100 shows promise in Parkinson’s treatment - Investing.com Australia

May 20, 2025

ZyVersa Therapeutics Highlights Published Study Reinforcing - GlobeNewswire

May 20, 2025

Breakthrough Study Reveals Key to Fighting Parkinson's: ZyVersa's Novel Drug Shows Promise in $13B Market - Stock Titan

May 20, 2025

May 12, 2025

ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq

May 12, 2025

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire

May 12, 2025

May 09, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN

May 09, 2025

May 08, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India

May 08, 2025

May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire

May 07, 2025

ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks

May 07, 2025

ZyVersa progresses with obesity inflammation treatment - Investing.com Australia

May 07, 2025

ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com

May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan

May 07, 2025

Apr 30, 2025